Cara Therapeutics, Inc. develops therapeutics. The Company offers novel drugs for the treatment of human diseases associated with pain and inflammation. Cara Therapeutics serves customers in the United States.

Current Report (Form 8-K | Period ending 2025-04-15)

Current Report (Form 8-K | Period ending 2025-04-11)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cara Therapeutics (CARA US)

Current Report (Form 8-K | Period ending 2025-04-15)

Current Report (Form 8-K | Period ending 2025-04-11)

Current Report (Form 8-K | Period ending 2025-04-01)

425 | Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Current Report (Form 8-K | Period ending 2025-03-24)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)